Who
Kim P. Kamdar
Director
Company insider
Files Form 4 as: Director, Sera Prognostics; Director, Singular Genomics Systems; Director and 10% owner, Evofem Biosciences; Director, Vyome Holdings; Director and 10% owner, Syndax Pharmaceuticals; 10% owner, Durata Therapeutics; 10% owner, Cadence Pharmaceuticals.
In numbers
- Trades disclosed
- 66
- Buys
- 5
- Sells
- 5
- Bought
- $377K
- Sold
- $366K
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 19 Mar 2014
- Last trade
- 10 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —22,426 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —3,421 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —34,494 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —34,494 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —5,263 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —5,263 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —22,426 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —3,421 at $0.00 | filing |
| 4 Feb 2026filed 4 Feb 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code J | —30,920 at $0.00 | filing |
| 4 Feb 2026filed 4 Feb 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code J | —3,231 at $0.00 | filing |
| 4 Feb 2026filed 4 Feb 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code J | —30,920 at $0.00 | filing |
| 4 Feb 2026filed 4 Feb 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code J | —3,231 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —15,596 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | Singular Genomics Systemsoption or derivative | SEC FORM 4 Code D | —666 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | Singular Genomics Systemsoption or derivative | SEC FORM 4 Code D | —1,541 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | Singular Genomics Systemsoption or derivative | SEC FORM 4 Code D | —2,466 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | Singular Genomics Systemsoption or derivative | SEC FORM 4 Code D | $22K2,466 at $8.84 | filing |
| 21 Feb 2025filed 25 Feb 2025 | Singular Genomics Systems | SEC FORM 4 Code D | —15,000 | filing |
| 21 Feb 2025filed 25 Feb 2025 | Singular Genomics Systems | SEC FORM 4 Code D | —3,763,985 | filing |
News
No headline names them, or the companies they trade most, lately.